Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alcon stock logo
ALC
Alcon
$85.46
+0.8%
$90.25
$80.48
$101.10
$42.12B0.951.18 million shs1.79 million shs
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$309.70
-0.8%
$277.63
$205.87
$317.54
$40.38B0.22929,711 shs1.34 million shs
Swedish Orphan Biovitrum stock logo
BIOVF
Swedish Orphan Biovitrum
$27.06
-15.4%
$29.99
$24.08
$32.25
$9.63B0.44205 shs785 shs
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
$523.92
+0.8%
$486.81
$356.14
$530.73
$42.13B1.55647,967 shs1.05 million shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alcon stock logo
ALC
Alcon
0.00%-0.85%-0.72%-5.64%-4.33%
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
0.00%+0.56%+7.16%+9.30%+101.29%
Swedish Orphan Biovitrum stock logo
BIOVF
Swedish Orphan Biovitrum
0.00%-15.41%-11.28%-5.75%+2.77%
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
0.00%+0.23%+3.78%+24.45%+4.03%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Alcon stock logo
ALC
Alcon
3.557 of 5 stars
3.45.00.80.03.10.81.3
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
4.045 of 5 stars
2.45.00.04.32.02.50.6
Swedish Orphan Biovitrum stock logo
BIOVF
Swedish Orphan Biovitrum
N/AN/AN/AN/AN/AN/AN/AN/A
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
3.7988 of 5 stars
1.45.00.03.73.12.51.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alcon stock logo
ALC
Alcon
2.80
Moderate Buy$106.1324.18% Upside
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
2.77
Moderate Buy$319.583.19% Upside
Swedish Orphan Biovitrum stock logo
BIOVF
Swedish Orphan Biovitrum
4.00
Strong BuyN/AN/A
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
2.78
Moderate Buy$546.004.21% Upside

Current Analyst Ratings Breakdown

Latest BIOVF, ALC, IDXX, and ALNY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/12/2025
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$330.00 ➝ $338.00
6/11/2025
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$515.00 ➝ $580.00
5/22/2025
Alcon stock logo
ALC
Alcon
Kepler Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
5/20/2025
Alcon stock logo
ALC
Alcon
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
5/19/2025
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold ➝ Hold$460.00 ➝ $510.00
5/14/2025
Alcon stock logo
ALC
Alcon
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy$102.00 ➝ $99.00
5/14/2025
Alcon stock logo
ALC
Alcon
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$110.00 ➝ $110.00
5/5/2025
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$548.00 ➝ $558.00
5/2/2025
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$331.00 ➝ $349.00
5/2/2025
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$300.00 ➝ $325.00
4/14/2025
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$450.00 ➝ $420.00
(Data available from 6/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alcon stock logo
ALC
Alcon
$9.91B4.25$5.56 per share15.37$43.70 per share1.96
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$2.25B17.96N/AN/A$0.52 per share595.58
Swedish Orphan Biovitrum stock logo
BIOVF
Swedish Orphan Biovitrum
$2.46B3.91$2.05 per share13.19$10.71 per share2.53
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
$3.90B10.81$12.43 per share42.15$19.48 per share26.90
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alcon stock logo
ALC
Alcon
$1.02B$2.2537.9825.982.1811.28%6.95%4.92%8/19/2025 (Estimated)
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
-$278.16M-$2.09N/A347.98N/A-11.49%-510.31%-6.48%7/30/2025 (Estimated)
Swedish Orphan Biovitrum stock logo
BIOVF
Swedish Orphan Biovitrum
$367.52M$1.0625.53N/A15.07%10.54%5.43%7/16/2025 (Estimated)
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
$887.87M$10.8248.4238.583.8322.76%57.35%26.97%8/5/2025 (Estimated)

Latest BIOVF, ALC, IDXX, and ALNY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
Alcon stock logo
ALC
Alcon
$0.77$0.73-$0.04$0.70$2.52 billion$2.33 billion
5/1/2025Q1 2025
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
-$0.37-$0.44-$0.07-$0.44$584.32 million$594.19 million
5/1/2025Q1 2025
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
$2.93$2.96+$0.03$2.96$998.25 million$998.43 million
4/29/2025Q1 2025
Swedish Orphan Biovitrum stock logo
BIOVF
Swedish Orphan Biovitrum
$0.2152$0.26+$0.0448$0.24$644.12 million$641.33 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Alcon stock logo
ALC
Alcon
N/AN/AN/AN/A4 Years
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
N/AN/AN/AN/AN/A
Swedish Orphan Biovitrum stock logo
BIOVF
Swedish Orphan Biovitrum
N/AN/AN/AN/AN/A
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
N/AN/AN/AN/AN/A

Latest BIOVF, ALC, IDXX, and ALNY Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/7/2025
Alcon stock logo
ALC
Alcon
annual$0.32700.3%5/14/20255/14/20255/15/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alcon stock logo
ALC
Alcon
0.21
2.70
1.66
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
8.88
3.04
2.98
Swedish Orphan Biovitrum stock logo
BIOVF
Swedish Orphan Biovitrum
0.31
1.04
0.71
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
0.31
1.16
0.81

Institutional Ownership

CompanyInstitutional Ownership
Alcon stock logo
ALC
Alcon
53.86%
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
92.97%
Swedish Orphan Biovitrum stock logo
BIOVF
Swedish Orphan Biovitrum
N/A
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
87.84%

Insider Ownership

CompanyInsider Ownership
Alcon stock logo
ALC
Alcon
1.52%
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
1.50%
Swedish Orphan Biovitrum stock logo
BIOVF
Swedish Orphan Biovitrum
N/A
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
0.98%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alcon stock logo
ALC
Alcon
25,599493.24 million485.75 millionOptionable
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
2,230130.39 million128.43 millionOptionable
Swedish Orphan Biovitrum stock logo
BIOVF
Swedish Orphan Biovitrum
1,772356.00 millionN/ANot Optionable
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
11,00080.42 million79.63 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Alcon stock logo

Alcon NYSE:ALC

$85.46 +0.69 (+0.82%)
Closing price 06/20/2025 03:59 PM Eastern
Extended Trading
$85.42 -0.05 (-0.06%)
As of 06/20/2025 04:09 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. Its cataract products include Centurion vision system, LenSx laser system, ARGOS biometer, LuxOR surgical ophthalmic microscope, SMARTCATARACT health platform, NGENUITY 3D visualization system, Verion reference unit and Verion digital marker, and ORA system for intra-operative measurements; custom pak surgical procedure packs; vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, and grieshaber and MIVS instruments, as well as scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; refractive surgery products, including WaveLight lasers and Contoura Vision used for LASIK treatment; EX-PRESS glaucoma filtration device; and implantable products, including AcrySof IQ products, such as monofocal IOLs and advanced technology IOLs for the correction of presbyopia and astigmatism at the time of cataract surgery. Its Vision Care segment provides daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, glaucoma, contact lens care, and ocular allergies; and ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.

Alnylam Pharmaceuticals stock logo

Alnylam Pharmaceuticals NASDAQ:ALNY

$309.70 -2.62 (-0.84%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$315.00 +5.31 (+1.71%)
As of 06/20/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Swedish Orphan Biovitrum stock logo

Swedish Orphan Biovitrum OTCMKTS:BIOVF

$27.06 -4.93 (-15.41%)
As of 06/20/2025 10:25 AM Eastern

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company also provides other products, such as Akynzeo, Tegsedi, Jyseleca, Kepivance, Aloxi, and Waylivra. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Sanofi, Apellis Pharmaceuticals Inc., ADC Therapeutics SA, and Cartesian Therapeutics, Inc. Swedish Orphan Biovitrum AB (publ) was incorporated in 1939 and is headquartered in Solna, Sweden.

IDEXX Laboratories stock logo

IDEXX Laboratories NASDAQ:IDXX

$523.92 +4.07 (+0.78%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$524.55 +0.63 (+0.12%)
As of 06/20/2025 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. Additionally, the company offers human medical point-of-care products and laboratory diagnostics services. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.